Pharmaceutical News

RSS

Intellect Neurosciences completes restructuring of balance sheet

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today it has completed a restructuring of its balance sheet. The result is the extinguishment of approximately $24 million of aggregate face amount plus accrued interest of debt and preferred stock through the issuance of common stock.

26 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases in the global marketplace in collaboration with local partners, is pleased to announce the formation of a Finder's Agreement with its licensee for crofelemer in China, Luye Pharma Group Ltd. (formerly Asiapharm).

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Enhancing residence time improves drug effectivity: Study

Studies led by Stony Brook University professor of chemistry Peter J. Tonge indicate that modifications that enhance the time a drug remains bound to its target, or residence time, may lead to better diagnostic and therapeutic agents.

26 Apr 2010

Driving evolution of antibiotic resistance backwards

The use of antibiotics to treat bacterial infections causes a continual and vicious cycle in which antibiotic treatment leads to the emergence and spread of resistant strains, forcing the use of additional drugs leading to further multi-drug resistance.

26 Apr 2010

Amlodipine benazepril capsules for treatment of hypertension launched in the US market

Dr. Reddy's Laboratories announced today that it launched amlodipine benazepril capsules (2.5mg/10mg, 5mg/10mg, 5mg/20mg, 10mg/20mg), a bioequivalent generic version of Lotrel Capsules, in the US market on April 23, 2010.

26 Apr 2010

Organic Science to launch national line of medical marijuana products

International Merchant Advisors, Inc. announced today that its wholly owned subsidiary, California based Organic Science, Inc., intends to launch a national line of medical marijuana products under the Organic Science brand name. According to data provided in the new CNBC article "Marijuana and Money", the medical marijuana national product market may be as large as $109 billion per year.

26 Apr 2010

Nycomed, Merck enter co-promotion agreement for Daxas in Canada and Europe

Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.

26 Apr 2010

Over 90% of seniors consume less vitamin D than currently recommended

According to legend, it was The Fountain of Youth that the famed Spanish explorer Ponce de Leon was seeking when he landed on the Floridian coast in 1513. It has long been said that he who drinks from the Fountain will have his youth restored. Without a doubt, the quest for eternal youth is as ancient as any pursuit. However, although we are now living longer than ever, there is now growing concern that quantity of years is not nearly as important as quality of those years.

26 Apr 2010

WCRI study finds cost per claim for prescription drugs to treat injured workers in Maryland higher

The cost per claim for prescription drugs used to treat injured workers in Maryland was slightly higher than in most study states in a new study by the Workers Compensation Research Institute (WCRI).

26 Apr 2010

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

New evidence shows immunization against "swine flu" in 1976 might provide individuals with some protection against the 2009 pandemic H1N1 influenza virus, according to new research from St. Jude investigators.

24 Apr 2010

Physician panel to discuss issues related to Qutenza at Investor Day

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City

24 Apr 2010

New research project to make anti-malarial drugs more affordable in Third World countries

Dr Geoff Brown, from the University of Reading's Department of Chemistry, is beginning a £400,000 project that could prove vital for the developing world in its ongoing fight against malaria. His research aims to make anti-malarial drugs more affordable in Third World countries where more than 1.5 million people die of the disease every year.

24 Apr 2010

Immunization campaigns to be launched simultaneously in 112 countries and territories

For the first time, immunization campaigns are being launched simultaneously tomorrow in 112 countries and territories in the World Health Organization Regions of the Americas, Eastern Mediterranean and Europe, with the goals of expanding immunization coverage and raising awareness of the importance of vaccines.

24 Apr 2010

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

Diabetes treatment regimens containing AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly controlled blood sugar levels, according to a two-year study presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #283).

24 Apr 2010

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

Teva Pharmaceutical Industries Ltd. announced today that a jury returned a verdict in the U.S. District Court for the District of New Jersey finding that Nycomed's U.S. Patent No. 4,758,579 is not invalid. The Court has reserved decision on the issue of what, if any, effect to give to the jury's determinations in connection with the obviousness-type double patenting defenses, which Teva has argued is to be decided by the Court.

24 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

Federal officials confirm a shift in Medicaid drug rebates

Kaiser Health News staff writer Christopher Weaver writes: "The federal agency that oversees Medicaid confirmed Thursday that some money states receive as rebates from drugmakers will now be redirected to the federal government to help pay for the new health overhaul" (Weaver, 4/22).

24 Apr 2010

Pharmaceutical News

Intellect Neurosciences completes restructuring of balance sheet

Covidien introduces PENNSAID to the U.S. market

Covidien launches EXALGO Extended-Release Tablets in the US

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Enhancing residence time improves drug effectivity: Study

Driving evolution of antibiotic resistance backwards

Amlodipine benazepril capsules for treatment of hypertension launched in the US market

Organic Science to launch national line of medical marijuana products

Nycomed, Merck enter co-promotion agreement for Daxas in Canada and Europe

Over 90% of seniors consume less vitamin D than currently recommended

WCRI study finds cost per claim for prescription drugs to treat injured workers in Maryland higher

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

Physician panel to discuss issues related to Qutenza at Investor Day

New research project to make anti-malarial drugs more affordable in Third World countries

Immunization campaigns to be launched simultaneously in 112 countries and territories

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Federal officials confirm a shift in Medicaid drug rebates

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News